Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:IRON NASDAQ:KRYS NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$124.23-2.9%$118.49$66.11▼$148.83$11.17B0.871.72 million shs1.01 million shsIRONDisc Medicine$74.65+0.1%$72.16$40.00▼$99.50$2.85B0.97516,695 shs448,197 shsKRYSKrystal Biotech$364.23+3.5%$336.39$130.50▼$382.54$10.37B0.5558,368 shs420,223 shsSMMTSummit Therapeutics$12.55-4.2%$14.90$12.25▼$30.98$10.45B-1.263.64 million shs5.02 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+1.83%-2.66%+31.28%+16.50%+92.51%IRONDisc Medicine+0.66%+0.31%-0.23%+10.93%+23.10%KRYSKrystal Biotech+4.96%+3.71%-5.49%+30.66%+138.34%SMMTSummit Therapeutics-4.10%-2.96%-6.50%-38.38%-54.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$124.23-2.9%$118.49$66.11▼$148.83$11.17B0.871.72 million shs1.01 million shsIRONDisc Medicine$74.65+0.1%$72.16$40.00▼$99.50$2.85B0.97516,695 shs448,197 shsKRYSKrystal Biotech$364.23+3.5%$336.39$130.50▼$382.54$10.37B0.5558,368 shs420,223 shsSMMTSummit Therapeutics$12.55-4.2%$14.90$12.25▼$30.98$10.45B-1.263.64 million shs5.02 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+1.83%-2.66%+31.28%+16.50%+92.51%IRONDisc Medicine+0.66%+0.31%-0.23%+10.93%+23.10%KRYSKrystal Biotech+4.96%+3.71%-5.49%+30.66%+138.34%SMMTSummit Therapeutics-4.10%-2.96%-6.50%-38.38%-54.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.80Moderate Buy$156.5025.98% UpsideIRONDisc Medicine 2.73Moderate Buy$104.4439.91% UpsideKRYSKrystal Biotech 2.83Moderate Buy$360.67-0.98% DownsideSMMTSummit Therapeutics 2.44Hold$26.15108.40% UpsideCurrent Analyst Ratings BreakdownLatest IRON, ABVX, KRYS, and SMMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026SMMTSummit Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$15.007/24/2026ABVXAbivax Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$180.007/24/2026SMMTSummit Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$45.00 ➝ $38.007/24/2026SMMTSummit Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $38.007/24/2026SMMTSummit Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight7/23/2026SMMTSummit Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral7/17/2026ABVXAbivax Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026IRONDisc Medicine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026SMMTSummit Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026SMMTSummit Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral7/14/2026KRYSKrystal Biotech Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$364.00 ➝ $396.00(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/AIRONDisc MedicineN/AN/AN/AN/A$19.52 per shareN/AKRYSKrystal Biotech$389.13M27.59$7.55 per share48.26$42.06 per share8.66SMMTSummit TherapeuticsN/AN/AN/AN/A$0.79 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%9/21/2026 (Estimated)IRONDisc Medicine-$212.18M-$6.62N/AN/AN/AN/A-36.94%-33.88%8/6/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4848.6939.16N/A53.92%19.25%17.62%8/3/2026 (Estimated)SMMTSummit Therapeutics-$1.08B-$1.12N/AN/AN/AN/A-168.94%-141.92%N/ALatest IRON, ABVX, KRYS, and SMMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026IRONDisc Medicine-$1.7124N/AN/AN/A$1.00 millionN/A8/3/2026Q2 2026KRYSKrystal Biotech$1.70N/AN/AN/A$121.83 millionN/A7/23/2026Q2 2026SMMTSummit Therapeutics-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A5/22/2026Q1 2026ABVXAbivax-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million5/5/2026Q1 2026IRONDisc Medicine-$1.6227-$1.65-$0.0273-$1.65$0.44 millionN/A5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million5/1/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.258.25IRONDisc Medicine0.0424.0024.00KRYSKrystal BiotechN/A9.469.06SMMTSummit TherapeuticsN/A6.966.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%IRONDisc Medicine83.70%KRYSKrystal Biotech86.29%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AIRONDisc Medicine3.76%KRYSKrystal Biotech13.10%SMMTSummit Therapeutics83.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6187.25 millionN/ANot OptionableIRONDisc Medicine3038.16 million36.73 millionNot OptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableSMMTSummit Therapeutics110797.75 million131.63 millionOptionableIRON, ABVX, KRYS, and SMMT HeadlinesRecent News About These CompaniesSummit Therapeutics (NASDAQ:SMMT) Hits New 12-Month Low - Time to Sell?July 28 at 2:20 PM | marketbeat.comKuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law FirmJuly 27 at 8:52 AM | prnewswire.comSummit Therapeutics Sees Unusually Large Options Volume (NASDAQ:SMMT)July 26 at 2:01 AM | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Earns Neutral Rating from HC WainwrightJuly 25 at 3:02 AM | americanbankingnews.comSMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival DataJuly 24, 2026 | msn.comTraders Purchase High Volume of Call Options on Summit Therapeutics (NASDAQ:SMMT)July 24, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down After Earnings MissJuly 24, 2026 | marketbeat.comSMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in FocusJuly 24, 2026 | zacks.comSummit Therapeutics (SMMT) Updates Phase III Survival Data, Is The Stock Still A Bargain?July 23, 2026 | finance.yahoo.comSummit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call TranscriptJuly 23, 2026 | seekingalpha.comSummit Therapeutics Inc. 2026 Q2 - Results - Earnings Call PresentationJuly 23, 2026 | seekingalpha.comSummit Therapeutics Q2 Earnings Call HighlightsJuly 23, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Releases Earnings Results, Beats Estimates By $0.08 EPSJuly 23, 2026 | marketbeat.comSummit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026July 23, 2026 | businesswire.comSMMT Shares Updated Ivonescimab Survival Data From NSCLC StudyJuly 23, 2026 | zacks.comHC Wainwright Reaffirms "Neutral" Rating for Summit Therapeutics (NASDAQ:SMMT)July 23, 2026 | marketbeat.comArcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney CancerJuly 22, 2026 | businesswire.comSummit Therapeutics: 'Buy' On Ivonescimab's November PDUFA And Impressive Partner DataJuly 22, 2026 | seekingalpha.comThese major drug stocks rally after Trump's zero tariff announcementJuly 22, 2026 | finbold.comFIvonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi StudyJuly 22, 2026 | businesswire.comSummit Therapeutics (SMMT) Expected to Announce Quarterly Earnings on ThursdayJuly 19, 2026 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetBy Jeffrey Neal Johnson | July 10, 2026Why Wall Street Still Sees Massive Upside for AeroVironment StockBy Thomas Hughes | June 30, 2026Drone Stocks Are Down, But Defense Backlogs Tell a Different StoryBy Thomas Hughes | July 8, 2026Abivax: Wall Street Catches Up to the DataBy Chris Markoch | July 7, 2026AeroVironment’s Stock Is Down, But Drone Demand Is Taking OffBy Jeffrey Neal Johnson | July 21, 2026IRON, ABVX, KRYS, and SMMT Company DescriptionsAbivax NASDAQ:ABVX$124.23 -3.77 (-2.95%) Closing price 04:00 PM EasternExtended Trading$125.24 +1.01 (+0.81%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Disc Medicine NASDAQ:IRON$74.65 +0.04 (+0.05%) Closing price 04:00 PM EasternExtended Trading$74.60 -0.05 (-0.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Krystal Biotech NASDAQ:KRYS$364.23 +12.41 (+3.53%) Closing price 04:00 PM EasternExtended Trading$363.80 -0.43 (-0.12%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Summit Therapeutics NASDAQ:SMMT$12.55 -0.55 (-4.20%) Closing price 04:00 PM EasternExtended Trading$12.47 -0.08 (-0.61%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
